ASH: Rituxan + CHOP Improves Survival of Indolent Lymphoma in Older Patients

For older patients with follicular lymphoma, the addition of Rituxan (rituximab, MabThera) to standard CHOP chemotherapy boosted overall response rates, prolonged time to treatment failure, and improved overall survival, German researchers said at the ASH conference.

"The addition of rituximab to CHOP in treating advanced stage follicular lymphoma significantly improves the outcome of patients with previously untreated follicular lymphoma, not only in young patients, but also in patients of advanced age," said Dr. Christian Buske, M.D., of the Klinikum Grosshadern in Munich.

Follicular lymphoma is an indolent lymphoma with an incidence that rises sharply with age, Dr. Buske noted. More than 40% of patients with follicular lymphoma are older than 60 at the time of diagnosis, and there is an age-specific incidence peaking above 75.

ASH abstract #482: Buske C et al. "Front-line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma -- Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)"

LymphomaInfo Social